PUBLIC LAW 116–22—JUNE 24, 2019  133 STAT. 958  the House of Representatives a report containing the results of  the study conducted under subsection (a) and recommendations  to improve the application and consistency of the requirements  under subsections (c) and (d) of section 565 of the Federal Food,  Drug, and Cosmetic Act (21 U.S.C. 360bbb–4) to support and expe- dite the research and development of medical countermeasures,  as applicable.  (d) PROTECTION OF NATIONAL SECURITY.—The Comptroller Gen- eral of the United States shall conduct the study and issue the  assessment and report under this section in a manner that does  not compromise national security.  (a) MEETING.—  Deadline.  (1) IN GENERAL.—Not later than 1 year after the date  of enactment of this Act, the Secretary of Health and Human  Services (referred to in this section as the ‘‘Secretary’’) shall  convene a meeting to discuss the potential role advancements  in genomic engineering technologies (including genome editing  technologies) may have in advancing national health security.  Such meeting shall be held in a manner that does not com- promise national security.  (2) ATTENDEES.—The attendees of the meeting under para- graph (1)—  (A) shall include—  (i) representatives from the Office of the Assistant  Secretary for Preparedness and Response, the National  Institutes of Health, the Centers for Disease Control  and Prevention, and the Food and Drug Administra- tion; and  (ii) representatives from academic, private, and  nonprofit entities with expertise in genome engineering  technologies, biopharmaceuticals, medicine, or bio- defense, and other relevant stakeholders; and  (B) may include—  (i) other representatives from the Department of  Health and Human Services, as the Secretary deter- mines appropriate; and  (ii) representatives from the Department of Home- land Security, the Department of Defense, the Depart- ment of Agriculture, and other departments, as the  Secretary may request for the meeting.  (3) TOPICS.—The meeting under paragraph (1) shall include  a discussion of—  (A) the current state of the science of genomic  engineering technologies related to national health security,  including—  (i) medical countermeasure development, including  potential efficiencies in the development pathway and  detection technologies; and  (ii) the international and domestic regulation of  products utilizing genome editing technologies; and  (B) national security implications, including—  SEC. 605. REVIEW OF THE BENEFITS OF GENOMIC ENGINEERING TECH- NOLOGIES AND THEIR POTENTIAL ROLE IN NATIONAL  SECURITY. 